


PHARMACEUTICAL 2017



Pfenex Inc. Rank 20 of 313





PHARMACEUTICAL 2017



Pfenex Inc. Rank 20 of 313

The relative strengths and weaknesses of Pfenex Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pfenex Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 430% points. The greatest weakness of Pfenex Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 175%, being 592% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	86,918
Cost of Goods Sold	5,313
Intangible Assets	10,878
Liabilities, Current	17,212
Liabilities, Non-Current	26
Other Assets	80
Other Compr. Net Income	0
Other Expenses	-209
Other Liabilities	5,739
Other Net Income	149
Property and Equipment	5,246
Research and Development	32,418
Revenues	60,194
Selling, General and Administrative Expense	17,340

Output Variable	Value in 1000 USD
Assets	103,122
Liabilities	22,977
Expenses	54,862
Stockholders Equity	80,145
Net Income	5,481
Comprehensive Net Income	5,481
Economic Capital Ratio	175%